Senomyx (SNMX) & US Stem Cell (USRM) Head to Head Review

Senomyx (NASDAQ:SNMX) and US Stem Cell (OTCMKTS:USRM) are both small-cap consumer staples companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, valuation, profitability, risk, earnings and institutional ownership.

Volatility & Risk

Senomyx has a beta of 1.33, indicating that its share price is 33% more volatile than the S&P 500. Comparatively, US Stem Cell has a beta of 6.26, indicating that its share price is 526% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Senomyx and US Stem Cell, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Senomyx 0 0 0 0 N/A
US Stem Cell 0 0 0 0 N/A

Insider & Institutional Ownership

34.6% of Senomyx shares are held by institutional investors. 13.0% of Senomyx shares are held by insiders. Comparatively, 16.7% of US Stem Cell shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Senomyx and US Stem Cell’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Senomyx -9.11% -15.80% -10.48%
US Stem Cell -21.01% N/A -66.41%

Earnings & Valuation

This table compares Senomyx and US Stem Cell’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Senomyx $29.32 million 2.46 -$1.26 million ($0.03) -49.67
US Stem Cell $5.52 million 1.43 -$3.48 million N/A N/A

Senomyx has higher revenue and earnings than US Stem Cell.

Summary

Senomyx beats US Stem Cell on 6 of the 9 factors compared between the two stocks.

About Senomyx

Senomyx, Inc. discovers, develops, and commercializes flavor ingredients and natural high intensity sweeteners primarily for the packaged food, beverage, and ingredient supply industries in the United States. The company develops and/or commercializes sweet, savory and salt flavor ingredients, bitter blockers and cooling agents. It sells various flavor ingredients directly to flavor companies. The company has collaboration agreements with Ajinomoto Co., Inc.; Firmenich SA; and PepsiCo, Inc. Senomyx, Inc. was founded in 1998 and is headquartered in San Diego, California.

About US Stem Cell

U.S. Stem Cell, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States. Its lead product candidates include MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells or cells from a patient's body for enhancing cardiac function in chronic heart failure patients; and AdipoCell, a patient-derived cell therapy for the treatment of acute myocardial infarction, chronic heart ischemia, and lower limb ischemia. The company's product development pipeline includes MyoCell SDF-1, an autologous muscle-derived cellular therapy for improving cardiac function in chronic heart failure patients. It is also developing MyoCath, a deflecting tip needle injection catheter that is used to inject cells into cardiac tissue in therapeutic procedures to treat chronic heart ischemia and congestive heart failure. In addition, the company provides physician and patient based regenerative medicine/cell therapy training services, cell collection, and cell storage services; and cell collection and treatment kits for humans and animals, as well operates a cell therapy clinic. The company was formerly known as Bioheart, Inc. and changed its name to U.S. Stem Cell, Inc. in October 2015. U.S. Stem Cell, Inc. was founded in 1999 and is headquartered in Sunrise, Florida.

Receive News & Ratings for Senomyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senomyx and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply